Overview
McDermott Will & Emery has advised MaaT Pharma, a late-stage biotechnology company leading the development of Microbiome Ecosystem TherapiesTM to improve the survival of cancer patients, on its EUR19.2 million offering, comprising a reserved offering of new ordinary shares to institutional investors and a public offering of new ordinary shares via the PrimaryBid platform, as well as a secondary offering of existing ordinary shares held by certain funds managed by Seventure Partners, at a price of EUR8 per share.
The McDermott team advising Maat Pharma included partners Bertrand Delafaye and Emmanuelle Trombe and associates Henri Nalbandyan and Amel El Mouttaki.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
